← Back to Clinical Trials
Recruiting NCT04711746

NCT04711746 Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04711746
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Pulmonary Embolism
Study Type INTERVENTIONAL
Enrollment 544 participants
Start Date 2021-02-01
Primary Completion 2026-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
blood sample

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 544 participants in total. It began in 2021-02-01 with a primary completion date of 2026-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The clonal hematopoiesis of indetermined prognosis (CHIP) has been described as risk factor for juvenile atherosclerosis. Moreover, some of CHIP genes are responsible of myeloproliferative disorders. Venous thrombosis are frequent in these disorders. The purpose of this project is to determine if CHIP is frequent in unprovoked pulmonary embolism and could be part of the pathophysiology.

Eligibility Criteria

Inclusion Criteria: * For cases : Previous proximal unprovoked pulmonary embolism, negative thrombophilia screening. * For control : Previous proximal provoked pulmonary embolism, negative thrombophilia screening. Exclusion Criteria: * Age superior to 65 years old, * Active cancer

Contact & Investigator

Central Contact

Simon SOUDET, MD

✉ soudet.simon@chu-amiens.fr

📞 03 22 88 72 89

Frequently Asked Questions

Who can join the NCT04711746 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Pulmonary Embolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04711746 currently recruiting?

Yes, NCT04711746 is actively recruiting participants. Contact the research team at soudet.simon@chu-amiens.fr for enrollment information.

Where is the NCT04711746 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT04711746 clinical trial?

NCT04711746 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 544 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology